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Efforts to create a mouse model that provides even a phenocopy of human multiple myeloma (MM) have been 
unsuccessful. In this issue of Cancer Cell, Bergsagel and colleagues describe an apparent solution to this 
problem by creating a model in which a MYC transgene containing a stop codon and flanking Igκ regulatory 
sequences is activated sporadically in germinal center B cells by AID-dependent somatic hypermutation that 
reverts the stop codon. Although much remains to be done to fully characterize this model, this approach is 
likely to impact the creation of sporadic models for other kinds of germinal center B cell tumors.The term “multiple myeloma” was sug-
gested by von Rustizky in 1873, when 
he found during autopsy multiple sepa-
rate bone marrow (myel-) tumors (-oma ) 
(Malpas et al., 2004). Multiple myeloma 
(MM) is a post-germinal center tumor 
of long-lived bone marrow (BM) plas-
mablasts/plasma cells (PC) that have 
undergone extensive somatic hypermu-
tation of Ig heavy chain (IgH) and Ig light 
chain (IgL) genes, antigen selection, and 
productive IgH switch recombination. 
Most tumors produce IgG or IgA, with 
IgM produced by only 1% of tumors. MM 
usually is preceded by a similarly age-
dependent premalignant tumor called 
monoclonal gammopathy of undeter-
mined significance (MGUS), the most 
common lymphoid tumor in humans, 
occurring in nearly 3% of individuals 
over the age of 50. For MGUS, the serum 
monoclonal Ig (M-Ig) typically is 5–30 g/l 
(normal polyclonal Ig is 7–15 g/l), with 
the tumor cells comprising no more than 
10% of BM mononuclear cells. Although 
MGUS usually remains stable for many years, there can be sporadic progres-
sion to frankly malignant MM express-
ing the same M-Ig at a rate of 1% per 
year. Smoldering MM, with a stable BM 
content of 10%–30% tumor cells, has 
a higher rate of sporadic progression. 
Frankly malignant MM usually is pro-
gressive and is associated with second-
ary pathologies, sometimes including 
osteoporosis, osteolytic lesions, ane-
mia, immunodeficiency, and decreased 
kidney function. Similar to long-lived PC, 
MGUS and MM have a strong depen-
dence on the BM microenvironment 
for survival and growth, although some 
individuals develop extramedullary MM, 
or PC leukemia, most often as a very 
late event. In contrast to long-lived PC, 
MGUS and MM have the ability to prolif-
erate at a low rate, usually with only a few 
percent of cycling cells until advanced 
stages of MM.
Early oncogenic events that are 
shared by MGUS and MM include pri-
mary IgH translocations (40%) and 
hyperdiploidy (50%), with dysregula-Cancer Ction of a CYCLIN D gene being a uni-
fying event for all tumors (Chng et al., 
2007). Based on these early events, it 
has been proposed that MGUS and MM 
can be classified into at least five dis-
tinct molecular groups (diseases) that 
are associated with different biological 
and clinical characteristics. No genetic 
abnormalities distinguish MM and 
MGUS, although activating RAS muta-
tions occur in 30%–40% of MM tumors 
but only 5% of MGUS tumors. Among 
shared genetic events that occur dur-
ing progression of MM, rearrangements 
of MYC (rarely MYCN) represent a very 
late progression event that appears to 
be associated with increased prolifera-
tion and decreased stromal cell depen-
dence.
The development of animal models 
for MM, including both de novo and 
syngeneic (Vanderkerken et al., 2003) 
or xenogenic (human MM into SCID-
Hu, SCID-Rab, or NOD-SCID mice) 
(Matsui et al., 2008; Yata and Yac-
coby, 2004) mouse transplant models ell 13, February 2008 ©2008 Elsevier Inc. 85
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PreviewsTable 1. Some Properties of Ex Vivo Murine Multiple Myeloma Models and Human Multiple Myeloma
 Balb/c PCT BCLXL × iMYC EµXBP1 WT C57BL6 Vk*MYC Human MM
Reference Potter, 2003 Cheung et al., 
2004
Carrasco et al., 
2007
Radl, 1999 Chesi et al., 
2008
Chng et al., 2007
Mouse strain Balb/c mixed # C57BL6 C57BL6 C57BL6 —
Tumor location EM EM, BM BM, EM BM BM BM
Major M-Ig IgA > IgG IgG > IgM IgM > IgG IgG > IgM IgG IgG > IgA
Ig hypermutation sometimes sometimes sometimes always (?) always always
Proliferation aggressive aggressive indolent indolent indolent indolent
Transplantable yes yes ? yes yes yes (to mice)
MYC dysregulation yes yes ? ? yes late only (?)
PCT, plasmacytoma; EM, extramedullary; BM, bone marrow; Vk*MYC, transgenic hu c-MYC with stop codon and Igκ regulatory elements; 
#, BCLXL on FVB/N background × iMYC on C57BL6 × 129SvJ background.has been an ongoing effort. Although 
the present work (Chesi et al., 2008) 
clearly provides the most promising 
de novo model, some of the previ-
ously described de novo models are 
described below (Table 1).
Nearly 50 years ago, Potter developed 
the transplantable Balb/c mouse perito-
neal plasmacytoma model (Potter, 2003). 
Important features of this model include 
susceptibility only in Balb/c and NZB 
mice, dependency on chronic inflamma-
tion, a long latency, and high penetrance. 
Significantly, Ig translocations that dys-
regulate MYC occur in all tumors, includ-
ing preneoplastic foci of aberrant PC that 
are found in the peritoneal granuloma. The 
introduction of other genes (e.g., v-abl, 
BCL2, BCLXL, IL6) transgenically or by 
infection with virus changed some of the 
characteristics (above) of this model, but 
the outcome still was mostly extramedul-
lary plasmacytoma, but sometimes with 
BM involvement. Despite the deficiencies 
of this model for MM, it has been seminal in 
many fundamental discoveries, including 
structure and rearrangements of Ig genes, 
biosynsthesis of Ig, MYC translocations, 
the role of IL6 and the microenvironment 
in the survival and growth of plasma cell 
tumors, identification of tumor susceptibil-
ity genes, and hybridoma formation.
Van Ness, Janz, and colleagues have 
reported that PC tumors were generated 
in mixed inbred mice that coexpressed 
c-MYC and BCLXL driven by Ig enhanc-
ers (Cheung et al., 2004). These short-
latency, aggressive tumors mostly were 
extramedullary plasmacytoma, but in 
some cases there also was BM involve-
ment that sometimes was associated 
with lytic bone disease.86 Cancer Cell 13, February 2008 ©2008 ElRadl and his colleagues reported a 
mouse model of MGUS in 1974, about 
10 years after MGUS was described in 
humans (Radl, 1999; Vanderkerken et al., 
2003). They found that C57BL6 mice had 
an age-dependent occurrence of serum 
M-Ig (IgG > IgM), with more than 50% of 
mice having at least one M-Ig at 2 years 
of age. The level of M-Ig was stable and 
was associated with BM PC that could 
be transplanted no more than twice. 
Subsequently, they identified seven con-
tinuously transplantable MM tumors in 
about 0.5% of 2-year-old C57BL6 mice. 
These tumors share most properties with 
human MM. Sometimes tumor cells were 
also found in spleen, perhaps reflecting 
the fact that the spleen is a significant 
site of hematopoiesis in mice but not in 
humans. Apart from the lack of Ig/MYC 
translocations by karyotype, very little 
is known about genetic abnormalities in 
these tumors, including identification of 
the genes that enable a high incidence 
of MGUS in these mice.
Recently, it was reported that an 
Eµ-XBP-1s transgenic C57BL6 model 
generated tumors that have the proper-
ties expected for MGUS and MM (Car-
rasco et al., 2007). However, there are 
major problems with this report: only a 
limited number of mice were analyzed 
for M-Ig and BM PC content, and more 
generally, the mice and tumors have 
been incompletely characterized: of six 
tumors, four produced IgM and only two 
produced IgG; only three of six tumors 
had somatically mutated Ig; evidence of 
clonality for many of these tumors was 
lacking or unconvincing; the tumors 
were not tested for transplantability; and 
analysis of the gene expression profiling sevier Inc.data does not seem consistent with a PC 
phenotype. In addition, nontransgenic 
C57BL6 mice should have an incidence 
of M-Ig spikes comparable to what they 
found for their transgenic mice, and it is 
unclear why they did not find this in their 
control mice (Chesi et al., 2008; Radl, 
1999). It is important that these prob-
lems are resolved before the Eµ-XBP-1s 
mouse can be accepted as a valid model 
for de novo MGUS and MM.
The present paper describes an ele-
gant model in which a MYC transgene 
containing a stop codon and flanking 
Igκ regulatory sequences is activated 
sporadically in germinal center B cells 
by AID-dependent somatic hypermuta-
tion that reverts the stop codon (Chesi 
et al., 2008). Instead of the expected 
generation of Burkitt’s lymphoma (which 
eventually occurred in 2 of 122 mice), all 
transgenic C57BL6 mice develop age-
dependent mono- or pauciclonal PC 
tumors that mainly produce IgG, have 
a high frequency of Ig mutations, are 
minimally proliferative, and are local-
ized in the bone marrow. The PC con-
tent of the BM is variable, consistent 
with a diagnosis of MGUS in some 
mice but MM in most mice. Anemia and 
osteoporosis occur in many mice, and 
some mice develop osteolytic lesions. 
In addition, chemotherapy sensitivity 
profiles for these tumors appear to be 
similar to clinical activity in human MM. 
Approximately one-third of these mice 
progress to extramedullary MM tumors 
that are localized in spleen or other lym-
phoid tissues, and sometimes in ascitic 
fluid. Immunization of the transgenic 
mice results in a similar age-dependent 
incidence of tumors, with about 25% 
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antigen, and about 75% of tumors pro-
gressing to extramedullary MM. One 
striking feature of human MM that is not 
present in most mice is the consistent 
suppression of polyclonal Ig (G, A, and 
M), but this may be due to low grade 
polyclonal PC transformation that does 
not generate detectable M-Ig.
Although the de novo model described 
here more fully recapitulates human 
MM than any of the other models (Table 
1), many questions remain. First, is the 
role of MYC the same in this model as in 
human MM? Although difficult to prove, 
the authors propose that the dysregula-
tion of MYC in these mice is a second-
ary event that drives one of the nascent 
MGUS tumors in the C57BL6 mouse 
towards MM. They provide evidence 
that MYC expression is increased in 
human MM compared to MGUS, but 
there is considerable overlap of MYC 
expression in human MGUS and MM. 
Moreover, full dysregulation of MYC 
by genomic rearrangements appears 
to be a late event in the progression 
of MM and is rarely, if ever, associ-
ated with the MGUS-to-MM transition 
(Chng et al., 2007). Second, is there 
truly an MGUS phase that progresses 
to MM in this model, or does the slow 
increase in tumor mass merely reflect 
the low rate of tumor proliferation? 
Third, apart from the dysregulation of MYC, what other genetic abnormalities 
occur in the MGUS, MM, and extramed-
ullary tumors in this model, and do they 
mimic the oncogenic events that have 
been described in human MGUS and 
MM tumors? Fourth, how much tumor 
proliferation occurs during transplanta-
tion, and what is the phenotype of the 
cell that proliferates? The answers to 
these and other questions not only will 
reveal how well this model mimics the 
human disease, but may also provide 
new insights into the pathogenesis and 
biology of human MGUS and MM.
A final point of interest in this study 
is the observation that AID-deficient 
C57BL6 mice do not develop age-
dependent MGUS (Chesi et al., 2008). 
Others have reported that AID is required 
for germinal center but not pregermi-
nal center lymphomagenesis and have 
suggested that errors in AID-depen-
dent somatic hypermutation and/or IgH 
switch recombination mechanisms are 
important contributors to pathogen-
esis of these tumors (Pasqualucci et 
al., 2008). There is no doubt that these 
AID-dependent processes sometimes 
cause oncogenic events (e.g., IgH trans-
locations) in lymphoma and MM. Still, it 
seems likely that long-lived PC, and per-
haps some kinds of germinal center or 
post-germinal center lymphocytes, can-
not be generated in the absence of AID. 
Therefore, one cannot conclude that AID Cancer Cis required to mediate genetic changes 
in all germinal center and post-germinal 
center tumors.
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